Abstract
Introduction: Esophageal cancer (EC) is an extremely aggressive neoplasm, diagnosed in about 17,000 Americans every year with a mortality rate of more than 80% within five years and a median overall survival of just 13 months. For decades, the go-to regimen for esophageal cancer patients has been the use of taxane and platinum-based chemotherapy regimens, which has yielded the field’s most dire survival statistics. Areas covered: Combination immunotherapy and a more robust molecular diagnostic platform for esophageal tumors could improve patient management strategies and potentially extend lives beyond the current survival figures. Analyzing a panel of biomarkers including those affiliated with taxane and platinum resistance (ERCC1 and TUBB3) as well as immunotherapy effectiveness (PD-L1) would provide oncologists more information on how to optimize first-line therapy for EC. Expert commentary: Of the 12 FDA-approved therapies in EC, zero target the genome. A majority of the approved drugs either target or are effected by proteomic expression. Therefore, a broader understanding of diagnostic biomarkers could give more clarity and direction in treating esophageal cancer in concert with a greater use of immunotherapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 33-45 |
| Number of pages | 13 |
| Journal | Expert Review of Anticancer Therapy |
| Volume | 17 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2 2017 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Oncology
- Pharmacology (medical)
Cite this
Basis for molecular diagnostics and immunotherapy for esophageal cancer. / Abdo, Joe; Agrawal, Devendra K.; Mittal, Sumeet K.
In: Expert Review of Anticancer Therapy, Vol. 17, No. 1, 02.01.2017, p. 33-45.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Basis for molecular diagnostics and immunotherapy for esophageal cancer
AU - Abdo, Joe
AU - Agrawal, Devendra K.
AU - Mittal, Sumeet K.
PY - 2017/1/2
Y1 - 2017/1/2
N2 - Introduction: Esophageal cancer (EC) is an extremely aggressive neoplasm, diagnosed in about 17,000 Americans every year with a mortality rate of more than 80% within five years and a median overall survival of just 13 months. For decades, the go-to regimen for esophageal cancer patients has been the use of taxane and platinum-based chemotherapy regimens, which has yielded the field’s most dire survival statistics. Areas covered: Combination immunotherapy and a more robust molecular diagnostic platform for esophageal tumors could improve patient management strategies and potentially extend lives beyond the current survival figures. Analyzing a panel of biomarkers including those affiliated with taxane and platinum resistance (ERCC1 and TUBB3) as well as immunotherapy effectiveness (PD-L1) would provide oncologists more information on how to optimize first-line therapy for EC. Expert commentary: Of the 12 FDA-approved therapies in EC, zero target the genome. A majority of the approved drugs either target or are effected by proteomic expression. Therefore, a broader understanding of diagnostic biomarkers could give more clarity and direction in treating esophageal cancer in concert with a greater use of immunotherapy.
AB - Introduction: Esophageal cancer (EC) is an extremely aggressive neoplasm, diagnosed in about 17,000 Americans every year with a mortality rate of more than 80% within five years and a median overall survival of just 13 months. For decades, the go-to regimen for esophageal cancer patients has been the use of taxane and platinum-based chemotherapy regimens, which has yielded the field’s most dire survival statistics. Areas covered: Combination immunotherapy and a more robust molecular diagnostic platform for esophageal tumors could improve patient management strategies and potentially extend lives beyond the current survival figures. Analyzing a panel of biomarkers including those affiliated with taxane and platinum resistance (ERCC1 and TUBB3) as well as immunotherapy effectiveness (PD-L1) would provide oncologists more information on how to optimize first-line therapy for EC. Expert commentary: Of the 12 FDA-approved therapies in EC, zero target the genome. A majority of the approved drugs either target or are effected by proteomic expression. Therefore, a broader understanding of diagnostic biomarkers could give more clarity and direction in treating esophageal cancer in concert with a greater use of immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=85006309044&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85006309044&partnerID=8YFLogxK
U2 - 10.1080/14737140.2017.1260449
DO - 10.1080/14737140.2017.1260449
M3 - Review article
C2 - 27838937
AN - SCOPUS:85006309044
VL - 17
SP - 33
EP - 45
JO - Expert Review of Anticancer Therapy
JF - Expert Review of Anticancer Therapy
SN - 1473-7140
IS - 1
ER -